File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Impact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma

TitleImpact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2011
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05 How to Cite?
Abstract
BACKGROUND: Although the therapeutic benefit of anti-viral treatment in the management of chronic hepatitis B infection (HBV) is well established, it remains uncertain if commencement of anti-viral therapy after hepatectomy in anti-viral naïve patients with hepatocellular carcinoma (HCC) would improve their survival outcome. METHODS: From September 2003 to December 2007, 42 patients (i.e. treatment group) were given Lamivudine (n = 39) or Entecavir(n = 4) after hepatectomy for HBV-related HCC. All these patients were anti-viral naïve before hepatectomy. Their preoperative data, tumor characteristics and survival outcome were compared with 94 patients without any antiviral treatment after hepatectomy (i.e. control group). RESULTS: The median age for treatment and control group were 57 and 55 years old respectively (P = 0.77). Patient demographics, preoperative liver function, tumor characteristics, liver function at the time of tumor recurrence were comparable between the two groups. Both disease-free and overall survival rates were significantly improved in the treatment group. The 1-, 3-, and 5-year overall survival rate in the treatment group was 88.1, 79.1, and 71.2% respectively, and in the control group was 76.5, 47.5, and 43.5% respectively (P = 0.005). The 1-, 3- and 5-year disease-free survival rate in the treatment group was 66.5, 51.4, and 51.4% respectively, and in the control group was 48.9, 33.8, and 33.8% respectively (P = 0.05). Subgroup analysis stratified against tumour stage and portal vein status showed that post-hepatectomy antiviral treatment confers a significant survival benefit in AJCC stage I/II tumours or HCCs without portal vein invasion. CONCLUSION: Anti-viral naïve HBV carriers could still benefit from the therapeutic effect of anti-viral treatment after curative treatment for hepatocellular carcinoma.
DescriptionOral Presentations
Persistent Identifierhttp://hdl.handle.net/10722/136094
ISSN
2013 Impact Factor: 2.468
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, ACYen_US
dc.contributor.authorChok, Ken_US
dc.contributor.authorYuen, WKen_US
dc.contributor.authorPoon, Ren_US
dc.contributor.authorLo, CMen_US
dc.contributor.authorFan, STen_US
dc.date.accessioned2011-07-27T02:02:44Z-
dc.date.available2011-07-27T02:02:44Z-
dc.date.issued2011en_US
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05en_US
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/136094-
dc.descriptionOral Presentations-
dc.description.abstractBACKGROUND: Although the therapeutic benefit of anti-viral treatment in the management of chronic hepatitis B infection (HBV) is well established, it remains uncertain if commencement of anti-viral therapy after hepatectomy in anti-viral naïve patients with hepatocellular carcinoma (HCC) would improve their survival outcome. METHODS: From September 2003 to December 2007, 42 patients (i.e. treatment group) were given Lamivudine (n = 39) or Entecavir(n = 4) after hepatectomy for HBV-related HCC. All these patients were anti-viral naïve before hepatectomy. Their preoperative data, tumor characteristics and survival outcome were compared with 94 patients without any antiviral treatment after hepatectomy (i.e. control group). RESULTS: The median age for treatment and control group were 57 and 55 years old respectively (P = 0.77). Patient demographics, preoperative liver function, tumor characteristics, liver function at the time of tumor recurrence were comparable between the two groups. Both disease-free and overall survival rates were significantly improved in the treatment group. The 1-, 3-, and 5-year overall survival rate in the treatment group was 88.1, 79.1, and 71.2% respectively, and in the control group was 76.5, 47.5, and 43.5% respectively (P = 0.005). The 1-, 3- and 5-year disease-free survival rate in the treatment group was 66.5, 51.4, and 51.4% respectively, and in the control group was 48.9, 33.8, and 33.8% respectively (P = 0.05). Subgroup analysis stratified against tumour stage and portal vein status showed that post-hepatectomy antiviral treatment confers a significant survival benefit in AJCC stage I/II tumours or HCCs without portal vein invasion. CONCLUSION: Anti-viral naïve HBV carriers could still benefit from the therapeutic effect of anti-viral treatment after curative treatment for hepatocellular carcinoma.-
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology Internationalen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleImpact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1936-0533&volume=5&issue=1&spage=419&epage=420, abstract no. PP29&date=2011&atitle=Impact+of+antiviral+therapy+on+the+survival+outcome+of+patients+after+major+hepatectomy+for+hepatitis+B-related+hepatocellular+carcinoma-
dc.identifier.emailChan, ACY: acchan@hku.hken_US
dc.identifier.emailChok, K: kennethchok@yahoo.com.hken_US
dc.identifier.emailYuen, WK: wkyuen@ha.org.hken_US
dc.identifier.emailPoon, R: poontp@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.authorityChan, ACY=rp00310en_US
dc.identifier.authorityPoon, R=rp00446en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.doi10.1007/s12072-010-9241-z-
dc.identifier.hkuros188334en_US
dc.identifier.volume5en_US
dc.identifier.issue1-
dc.identifier.spage419en_US
dc.identifier.epage420en_US
dc.identifier.isiWOS:000300105300001-
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats